Kyowa Kirin Highlights New Mogamulizumab Data in Cutaneous T-Cell Lymphoma at WCCL 2026

Kyowa Kirin announced that multiple analyses evaluating mogamulizumab in relapsed or refractory mycosis fungoides (MF) and Sézary syndrome (SS) will be presented at the 2026 World Congress of Cutaneous Lymphomas (WCCL), providing new insights into the therapy's clinical utility, patient experience, and real-world performance.¹

The presentations draw from a range of evidence sources, including patient-reported outcomes, comparative-effectiveness studies, molecular profiling, and observational clinical practice data. Together, the findings aim to expand understanding of mogamulizumab beyond the pivotal studies that supported its approval for adult patients with relapsed or refractory MF or SS after at least one prior systemic therapy.¹

"The research being presented at WCCL reflects our continued commitment to generating evidence beyond initial clinical trials for mogamulizumab in patients with relapsed or refractory mycosis fungoides and Sézary syndrome," said Daniela van Eickels, MD, PhD, MPH, chief medical officer of Kyowa Kirin North America.¹

What new evidence will be presented for mogamulizumab?

Among the featured presentations is an analysis from the PROSPER study evaluating symptoms and health-related quality of life in patients treated with mogamulizumab. Additional oral presentations will compare outcomes from the Phase 3 MAVORIC trial with real-world patient cohorts receiving alternative therapies and assess overall survival among patients treated in routine clinical practice.¹

Researchers will also present findings from the MOGA-2MG-Q4W clinical trial examining targeted sequencing and molecular biomarkers in patients with relapsed or refractory MF or SS receiving mogamulizumab.¹

The breadth of data reflects a growing emphasis within oncology on supplementing traditional clinical trial findings with real-world evidence and patient-centered outcomes to better characterize treatment effectiveness.²

Why is mogamulizumab important in cutaneous T-Cell lymphoma?

MF and SS are rare forms of cutaneous T-cell lymphoma, a group of non-Hodgkin lymphomas that originate from malignant T lymphocytes and primarily affect the skin. Patients with advanced or relapsed disease often face limited treatment options and can experience substantial symptom burden, including severe itching, skin lesions, infections, and diminished quality of life.³

Mogamulizumab is a humanized monoclonal antibody that targets CC chemokine receptor 4 (CCR4), a protein frequently expressed on malignant T cells. The therapy received regulatory approval following results from the Phase 3 MAVORIC study, which demonstrated improved progression-free survival compared with vorinostat in patients with relapsed or refractory MF and SS.⁴

What have previous studies shown for mogamulizumab?

The Phase 3 MAVORIC trial compared the CCR4-targeted monoclonal antibody with vorinostat in previously treated patients. The study demonstrated a median progression-free survival of 7.7 months with mogamulizumab versus 3.1 months with vorinostat, along with higher overall response rates, particularly among patients with Sézary syndrome.⁴ Investigators also observed improvements in blood, skin, and lymph node disease compartments.⁴ Subsequent analyses have suggested that mogamulizumab may provide durable disease control in some patients, supporting its role as an important treatment option for relapsed or refractory cutaneous T-cell lymphoma.⁴

How is real-world evidence shaping future treatment strategies?

The upcoming WCCL presentations underscore the increasing role of real-world and translational research in hematologic malignancies. While randomized clinical trials remain the foundation for regulatory decision-making, observational studies and patient-reported outcomes can provide additional insight into long-term treatment performance, quality-of-life impacts, and outcomes across broader patient populations.²

As precision medicine approaches continue to evolve, biomarker-driven analyses may also help identify patient subgroups most likely to benefit from targeted therapies such as mogamulizumab. The new data could further inform treatment strategies for clinicians managing these challenging and often difficult-to-treat malignancies.¹

References

1. Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL. https://www.globenewswire.com/news-release/2026/06/10/3309620/0/en/kyowa-kirin-to-present-new-complementary-evidence-further-defining-clinical-utility-of-mogamulizumab-in-cutaneous-t-cell-lymphoma-at-2026-wccl.html
2. Sherman RE, Anderson SA, Dal Pan GJ, et al. (2016 Dec). Real-World Evidence—What Is It and What Can It Tell Us? N Engl J Med. https://pubmed.ncbi.nlm.nih.gov/27959688/
3. Willemze R, Cerroni L, Kempf W, et al. (2019).The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. https://pubmed.ncbi.nlm.nih.gov/30635287/
4. Kim YH, Bagot M, Pinter-Brown L, et al. (2018). Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. https://pubmed.ncbi.nlm.nih.gov/30100375/